S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)

Cytokinetics (CYTK) Stock Forecast & Price Target

$33.57
+0.09 (+0.27%)
(As of 12/1/2023 ET)
Compare
Today's Range
$32.39
$33.58
50-Day Range
$26.88
$36.32
52-Week Range
$25.98
$47.49
Volume
1.70 million shs
Average Volume
1.04 million shs
Market Capitalization
$3.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.87

Cytokinetics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings

Analysts' Consensus Price Target

$59.87
78.33% Upside
High Forecast$80.00
Average Forecast$59.87
Low Forecast$42.00
TypeCurrent Forecast
12/1/22 to 12/1/23
1 Month Ago
11/1/22 to 11/1/23
3 Months Ago
9/2/22 to 9/2/23
1 Year Ago
12/1/21 to 12/1/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
13 Buy rating(s)
13 Buy rating(s)
9 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$59.87$59.29$58.21$63.83
Predicted Upside78.33% Upside62.47% Upside55.36% Upside46.98% Upside
Get Cytokinetics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.


CYTK Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CYTK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cytokinetics Stock vs. The Competition

TypeCytokineticsMedical CompaniesS&P 500
Consensus Rating Score
2.93
2.67
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside78.33% Upside760.62% Upside2,867.39% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/9/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+43.84%
11/7/2023B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$66.00+91.69%
11/1/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$58.00+66.38%
10/20/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$60.00+82.87%
10/9/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$71.00+128.81%
10/9/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$59.00 ➝ $65.00+112.42%
8/15/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Ruiz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
8/15/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$58.00+80.69%
8/15/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$58.00+80.69%
8/4/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$60.00+76.16%
6/22/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$52.00 ➝ $54.00+49.50%
5/5/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$61.00 ➝ $62.00+59.14%
4/2/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$50.00 ➝ $42.00+19.35%
3/6/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Salim Syed
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$80.00+100.85%
3/1/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$55.00 ➝ $54.00+24.74%
12/20/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$60.00+36.30%
(Data available from 12/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CYTK Price Target - Frequently Asked Questions

What is Cytokinetics's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Cytokinetics stock is Moderate Buy based on the current 1 hold rating and 14 buy ratings for CYTK. The average twelve-month price prediction for Cytokinetics is $59.87 with a high price target of $80.00 and a low price target of $42.00. Learn more on CYTK's analyst rating history.

Do Wall Street analysts like Cytokinetics more than its competitors?

Analysts like Cytokinetics more than other Medical companies. The consensus rating score for Cytokinetics is 2.93 while the average consensus rating score for medical companies is 2.67. Learn more on how CYTK compares to other companies.

Does Cytokinetics's stock price have much upside?

According to analysts, Cytokinetics's stock has a predicted upside of 67.36% based on their 12-month stock forecasts.

What analysts cover Cytokinetics?

Cytokinetics has been rated by B. Riley, Cantor Fitzgerald, HC Wainwright, JMP Securities, Needham & Company LLC, and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:CYTK) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -